Skip to main content
Skip to content
Case File
d-32537House OversightFinancial Record

Capital Markets Overview for Public Cannabis Companies (2017)

The passage provides aggregate financing data and market listings for cannabis‑related public companies, but it contains no specific allegations, transactions, or individuals that suggest misconduct o US cannabis firms raised $1.35 bn across 78 deals in the 12‑month period ending Sep 30 2017. Canada contributed $1.056 bn of that capital; Australia $26 m. Four cannabis firms traded on Nasdaq, one R

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024757
Pages
1
Persons
0
Integrity
No Hash Available

Summary

The passage provides aggregate financing data and market listings for cannabis‑related public companies, but it contains no specific allegations, transactions, or individuals that suggest misconduct o US cannabis firms raised $1.35 bn across 78 deals in the 12‑month period ending Sep 30 2017. Canada contributed $1.056 bn of that capital; Australia $26 m. Four cannabis firms traded on Nasdaq, one R

Tags

regulatory-enforcementcapital-marketsfinancial-flowcannabis-industryfinancial-datasechouse-oversightfinrastock-trading

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
CHAPTER VII Capital Markets for Cannabis Companies Capital Raised by Publicly Traded Cannabis-Related Companies (LTM ended September 30, 2017) $1600 $1400 $1200 $1000 $800 (SU.S. millions) $600 $400 $200 $0 Canada United States Australia Total Amount Raised $1056 $268 $26 $1350 Number of Deals 60 15 3 78 Average Deal Size $18 $18 $9 $17 Source: S&P Global Market Intelligence. In December 2017, a $317 million financing was completed by GW Pharmaceuticals (Nasdaq: GWPH), but the transaction occurred outside the date range of the analysis. Due to the size of the transaction, it is worth noting here. = Public Capital Markets: United States As of November 30, 2017, four cannabis-related companies were trading on Nasdaq (all in the phar- maceutical industry and focused on receiving FDA approval for selected cannabinoid applications), one was trading on the NYSE (a real estate investment trust, or REIT, focused on the acquisition and management of properties leased to state-licensed operators for their regulated medical-use cannabis facilities), two were trading on the NYSE American (both in the pharmaceutical industry) and more than 200 cannabis-related companies were trading on the OTC. Most of the companies trading on the OTC (i) are “penny” stocks that trade at less than $5.00 per share, (ii) have limited trading volume and liquidity, (iii) have significant price volatility, and (iv) have little or no institutional investor support. The U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA) have historically expressed concerns regarding the “penny” stock industry in general and both have issued alerts to warn investors about potential scams associated with purported cannabis-related stocks. In addition, the SEC has initiated actions against numerous purported cannabis-related companies and executives for fraud, insider trading, stock manipulation and other activities. The following table provides a summary of cannabis-related companies traded on the U.S. stock markets. © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 121

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.